Tisotumab vedotin是一种针对组织因子（tissue factor, TF）的抗体-药物偶联物（ADC），由全人源单克隆抗体(TF-011)与Monomethyl Auristatin E (MMAE)耦合而成，具有显著抗肿瘤活性，适用于晚期或转移性实体瘤的治疗研究。

Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.

Ozuriftamab vedotin 是一种抗体偶联药物（ADC），可用于生命科学相关研究。其 CAS 号为 2460400-11-5。

Propargyl-C8-amido-PEG2-NHS ester is a non-cleavable linker composed of two PEG units, primarily employed for the synthesis of antibody-drug conjugates (ADCs). This compound serves as an essential constituent that facilitates the conjugation of antibodies to drugs, enabling the targeted delivery of therapeutic agents.

Mal-C2-NHS ester is a noncleavable linker compound commonly employed for the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH是一种可降解的ADC linker，用于合成可用于合成ADC(抗体药物偶联分子)。